Resumen de Glargine and Cancer: Vista Glargine and Cancer
The early vital information on the biotransformation of insulin glargine (11) was seemingly ignored for many years, with research groups having chosen instead to focus on the in vitro IGF-1 binding properties of the parent compound insulin glargine. [...]little further development has occurred until the current articles by Bolli and colleagues (1,2). There is acknowledgment by the authors that it is also necessary and advisable to examine the metabolism of insulin glargine after prolonged exposure and at even higher doses, which are sometimes used in obese and insulin-resistant individuals. [...]the virtual absence of the parent compound insulin glargine in the circulation after its subcutaneous injection invalidates the submission that the in vitro findings of enhanced IGF-1 binding and mitogenicity of insulin glargine has a clinical correlate, especially as insulin glargine is extensively and quickly metabolized in the subcutaneous tissue and in the systemic circulation to its metabolites Ml and M2, both of which have lesser metabolic and similar mitogenic potency to human insulin (15,26).
